You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Pain relief caused by coronavirus may help explain its spread: Scientists

The novel coronavirus which causes Covid-19 may relieve pain, according to a new study which could explain why nearly 50% of the infected people experience few or no symptoms

Topics
Scientists | Coronavirus Tests | Coronavirus

Press Trust of India  |  Houston 

Coronavirus

The novel which causes COVID-19 may relieve pain, according to a new study which could explain why nearly 50 per cent of the infected people experience few or no symptoms, even though they are able to spread the disease.

According to the scientists, including Rajesh Khanna from the University of Arizona in the US, nearly half of COVID-19 transmission occurs prior to the onset of symptoms, and 40 per cent of COVID-19 infections are asymptomatic.

"It made a lot of sense to me that perhaps the reason for the unrelenting spread of COVID-19 is that in the early stages, you're walking around all fine as if nothing is wrong because your pain has been suppressed," Khanna said.

In the research, published in the journal PAIN, the raised the possibility that pain, as an early symptom of COVID-19, may be reduced by the spike protein as it silences the "body's pain signaling pathways."

Early in the pandemic, established that the novel SARS-CoV-2 spike protein uses the human cells' angiotensin-converting enzyme 2 (ACE2) receptor to enter the body.

Later in June, two studies published in the preprint server bioRxiv pointed to neuropilin-1 as a second receptor for SARS-CoV-2, the researchers said.

"That caught our eye because for the last 15 years my lab has been studying a complex of proteins and pathways that relate to pain processing that are downstream of neuropilin," said Khanna.

"So we stepped back and realised this could mean that maybe the spike protein is involved in some sort of pain processing," he added.

One of the biological pathways signal through which the body feels pain is via a protein named vascular endothelial growth factor-A (VEGF-A) that plays an essential role in blood vessel growth but also has been linked to diseases such as cancer, and rheumatoid arthritis, the said.

They added that most recently this protein has been linked to COVID-19.

Like a key in a lock, when VEGF-A binds to the receptor neuropilin, it initiates a cascade of events resulting in the hyperexcitability of neurons, which leads to pain, the study noted.

Khanna and his research team found that the SARS-CoV-2 spike protein binds to neuropilin in exactly the same location as VEGF-A.

They performed a series of lab experiments, and in rodent models to test their hypothesis that the SARS-CoV-2 spike protein acts on the VEGF-A/neuropilin pain pathway.

The researchers used VEGF-A as a trigger to induce excitation of nerve cells which create pain, then added the SARS-CoV-2 spike protein.

"Spike completely reversed the VEGF-induced pain signaling. It didn't matter if we used very high doses of spike or extremely low doses -- it reversed the pain completely," Khanna said.

The scientists further examined neuropilin as a new target for non-opioid pain relief.

During the study, Khanna tested existing small molecule neuropilin inhibitors developed to suppress tumour growth in certain cancers and found they provided the same pain relief as the SARS-CoV-2 spike protein when binding to neuropilin.

"We are moving forward with designing small molecules against neuropilin, particularly natural compounds, that could be important for pain relief," Khanna said.

"We have a pandemic, and we have an opioid epidemic. They're colliding. Our findings have massive implications for both. SARS-CoV-2 is teaching us about viral spread, but COVID-19 has us also looking at neuropilin as a new non-opioid method to fight the opioid epidemic," he added.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Fri, October 02 2020. 17:58 IST
RECOMMENDED FOR YOU